Symdeko

Chemical Nametezacaftor and ivacaftor
Dosage FormTablet (oral; 50 mg tezacaftor/75 mg ivacaftor and 75 mg ivacaftor, 100 mg tezacaftor/150 mg ivacaftor and 150 mg ivacaftor)
Drug ClassCFTR potentiators
SystemRespiratory
CompanyVertex Pharms Inc
Approval Year2018

Indication

  • Symdeko is indicated for the treatment of patients with cystic fibrosis (CF) age 6 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence.
Last updated on 2/3/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Symdeko (tezacaftor and ivacaftor) Prescribing Information2019Vertex Pharmaceuticals